Eli Lilly to invest $3 billion in China over next decade

BEIJING, March 11 (Reuters) - Eli Lilly LLY.N plans to invest $3 billion over the next decade to expand supply chain capacity in China and build production capacity for type-2 diabetes and obesity treatment orforglipron, the pharmaceuticals giant said in a statement.

The company submitted marketing application for orforglipron to China's drug regulator at the end of 2025, it said.

It also aims to establish a localised manufacturing and supply system for oral solid dosage forms, the statement showed.